IMPLANET Raises Additional $11 Million to Fuel Deployment

IMPLANET Raises Additional $11 Million to Fuel Deployment
4/26/2010

BORDEAUX, France, April 26, 2010 /PRNewswire/ -- Thanks to promising commercial debut of its products (Surgical implants for Orthopedic and Spine surgery) and its Healthcare Information Technologies service offer (fully integrated and automated patient/product tracking and supply chain) IMPLANET S.A. raises an additional EUR 8 million (USD 11 million).

IMPLANET is proud to welcome a reference new institutional investor, CM-CIC Private Equity which brings EUR 4 million.

Led by Edmond de Rothschild Investment Partners, historical shareholders, Wellington Partners, Seventures Partners et Auriga Partners along with founders, management and several domain reference private investors such as Marie-Helene PLAIS-COTREL (ex Sofamor-Danek) continue to support IMPLANET since inception in 2007 and together provide EUR 4 million.

Erick CLOIX (CEO IMPLANET) declares: "This new round of financing concludes a first cycle of 3 years during which 30 million Euros were invested to prepare and develop a novel type of Healthcare Company addressing, at last, the paradigm shifting challenges of quality, security and financing of healthcare everywhere, particularly in Europe and the USA. The current economic and financial crisis along with the US health care reform in the USA is a catalyst for our technologies, our services and our business model. The new 2010-2012 cycle which opens for us looks formidable with opportunities and conquests."

About Implanet

Implanet is a Medical Device and Healthcare Information Technology company based in Bordeaux, France. IMPLANET was incorporated in early 2007 and currently employs 45 full time employees and is already present within 8 countries. IMPLANET designs and manufactures surgical implants (HIP, KNEE, SPINE, and ARTHROSCOPY) exclusively in France and in Europe. These products are tested and registered under CE & FDA guidelines and standards by independent US and French registered testing laboratories. IMPLANET designs and develops unique healthcare information technologies applications for the tracking and tracing of Medical devices/Drugs and patients as well as healthcare supply chain optimization for both suppliers and hospitals under the brand name BEEP N TRACK . IMPLANET is also sole proprietor of various invention patents in France, Europe the USA and Asia on its surgical products and its Information Technologies.

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.